On 6 Nov 2026, Accretion Nutraveda was priced at ₹329.00, or 35.2× trailing earnings, against an industry P/E of 28.7×. Sales and net profit grew 126% and 162% a year over 3 years, with ROCE of 17% and ROE of 25%. Debt is 0.12× equity. It is listed on an SME platform with a market cap of ₹238 Cr, ranked 91st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 72% over the past year.
- ₹305.00
- ₹333.00
- ₹305.00
- ₹311.00
- 16K
Health check
- ReturnsAhead
+72.1% over a year, better than 6 of 7 peers.
- Price tagPricier
P/E 35.2 vs industry 28.7.
- GrowthStrong
Sales +126.2%, profit +162.3% a year over 3 years.
- ProfitabilityAverage
ROCE 17.0% vs peer median 17.9%.
- Balance sheetFair
Debt 0.12× equity, interest covered 14.7×, Piotroski 4 of 9.
- Red flags2 to check
Quarterly profit down 50.8% on a year ago.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹238 Cr
- Small cap
- P/E
- 35.2
- Industry 28.7
- Price to book
- 6.71
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 25.0%
- Peers 14.7%
- ROCE
- 17.0%
- Peers 17.9%
- Debt to equity
- 0.12
- Debt ₹4.23 Cr
- EPS (TTM)
- ₹9.35
- OPM (TTM)
- 18.0%
- Net margin 15.1%
- Sales growth
- −9.9%
- Latest quarter vs a year ago
- Profit growth
- −50.8%
- Latest quarter vs a year ago
- Price to sales
- 7.09
- EV/EBITDA 29.6
Strengths and risks
Strengths
- Return on equity of 25.0%.
Risks to check
- Quarterly profit down 50.8% on a year ago.
- Quarterly sales down 9.9% on a year ago.
About Accretion Nutraveda
Accretion Nutraveda Limited manufactures and supplies ayurvedic, nutraceutical, and wellness formulations in India and internationally. The company offers nutraceuticals products, including formulation for brain, memory and neuron care, UTI care, cardiac care, liver care, protein supplement, pediatric care, git care, effervescent, joint and bone care, immunity booster, gynec care, hair, skin, nail care, and infertility and PCOS care. It also provides…
- Headquarters
- Ahmedabad
- Sector
- Healthcare
- ISIN
- INE1KVQ01019
- Website
- accretionnutraveda.com
Price range
- Avg volume (3M)
- 7.8K
- 1-year return
- plus 72.1%
- From 52-week high
- minus 5.5%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| ANLAccretion Nutraveda | 329.00 | plus 5.79% | 238 | 35.2 | 6.71 | 17.0% | 25.0% | 18.0% | 126.2% | 162.3% | 0.00% | plus 72.1% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- +126.2%
- Profit CAGR 3Y
- +162.3%
- ROE
- 25.0%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 2.9 | 5 | 16 | 33.6 | |
| – | +72.4% | +219.7% | +110.0% | |
| 2.1 | 3.6 | 12.3 | 26.7 | |
| 0.8 | 1.4 | 3.7 | 6.9 | |
| 27.1% | 28.2% | 23.3% | 20.6% | |
| −0 | −0 | −0.1 | 0 | |
| 0.2 | 0.2 | 0.3 | 0.5 | |
| 0.3 | 0.3 | 0.2 | 0.3 | |
| – | – | – | −0 | |
| 0.3 | 0.9 | 3.2 | 6.2 | |
| 2.4% | 10.1% | 20.7% | 18.4% | |
| 0.3 | 0.8 | 2.5 | 5.1 | |
| – | +192.9% | +204.3% | +102.7% | |
| 0.39 | 1.14 | 3.45 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0.4 | 0.4 | 0.5 | 7.2 | |
| −0.1 | 0.7 | 4.6 | 28.2 | |
| 2 | 2.2 | 3.9 | 4.2 | |
| 1.8 | 1.4 | 1.6 | 2.1 | |
| 4.1 | 4.6 | 10.5 | 41.8 | |
| 1.5 | 1.4 | 1.8 | 7.6 | |
| – | 0.1 | – | 6 | |
| 0.1 | 0.1 | 0 | 9.7 | |
| 2.5 | 3 | 8.7 | 18.5 | |
| 4.1 | 4.6 | 10.5 | 41.8 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0.7 | 0.2 | −2.2 | −9.4 | |
| −0 | −0.2 | −0.9 | −14.5 | |
| −0.6 | −0 | 3 | 25.2 | |
| 0 | 0 | −0.1 | 1.3 | |
| −0 | −0.2 | −0.9 | −6 | |
| 0.7 | 0.1 | −3.1 | −15.5 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.